JP Morgan Chase’s Lucira Health, Inc. Common Stock LHDX Stock Holding History

JP Morgan Chase’s Portfolio LHDX Stock Details LHDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,100	Closed	–	–	7484
2022 Q4	$0	Buy	1,100 +1,092	+13,650%	+$697	﹤0.01%	7255
2022 Q3	$0	Buy	+8	New	+$18	﹤0.01%	7071
2022 Q1	–	Sell	-463	Closed	-$4K	–	7206
2021 Q4	$4K	Buy	+463	New	+$2.94K	﹤0.01%	6452
2021 Q2	–	Sell	-286,067	Closed	-$3.46M	–	6726
2021 Q1	$3.46M	Buy	+286,067	New	+$5.67M	﹤0.01%	3284

Other funds holding LHDX

Eclipse Ventures Palo Alto, California $2.57B AUM

Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Resolute Advisors San Francisco, California $417M AUM 60.99% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

JP Morgan Chase's LHDX Position: Q1 2023 in Review

JP Morgan Chase sold out of Lucira Health, Inc. Common Stock (LHDX) in Q1 2023, closing a stake of 1,100 shares.

JP Morgan Chase first reported a position in LHDX in Q1 2021 and held it in 4 quarters. The position peaked at $3.46M in Q1 2021. 6 funds tracked by Wall St. Rank hold LHDX as of Q1 2023.

JP Morgan Chase reported no remaining Lucira Health, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
JP Morgan Chase sold 1,100 Lucira Health, Inc. Common Stock shares in Q1 2023.
JP Morgan Chase first reported a position in Lucira Health, Inc. Common Stock in Q1 2021 and held it in 4 quarters.
JP Morgan Chase's Lucira Health, Inc. Common Stock position peaked at $3.46M in Q1 2021.
6 funds tracked by Wall St. Rank held Lucira Health, Inc. Common Stock as of Q1 2023.

Based on JP Morgan Chase's 13F filing for Q1 2023, filed 11 May 2023.